Combination locoregional and systemic therapies in hepatocellular carcinoma

Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis